CAMBRIDGE, Mass., July 11, 2017 /PRNewswire-USNewswire/ -- Spero Therapeutics, Inc., a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that Cristina Larkin, Chief Commercial Officer, and Mike Pucci, Executive Director, Early Drug Discovery will be participating in two separate panel discussions at the 2017 Anti-Infectives Partnering & Deal-Making Summit to be held July 13-14 in Baltimore, Maryland. The summit will discuss the various types and availability of economic incentives to spur innovation and development of therapies to address rapidly emerging global health threats.
Details of the panel discussions are as following:Session Name: Funding and Partnering with US Government AgenciesDate and time: Thursday, July 13, 2017 at 4:50 p.m. Eastern Time (ET)Location: Royal Sonesta, Baltimore
Session Name: Pricing and P&T Committee's Role in Determining Novel Antibiotic UsageDate and time: Friday, July 14, 2017 at 9:20 a.m. Eastern Time (ET)Location: Royal Sonesta, Baltimore
About SperoSpero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to developing a novel and highly differentiated pipeline of antibacterials focused on unmet needs of patients with drug resistant bacterial infections. Spero Therapeutics is advancing two lead programs in parallel, SPR994 and SPR741. SPR994 is a first in class oral agent that has demonstrated potent in vitro and in vivo activity against a wide variety of Gram-negative bacteria, including extended-spectrum beta-lactamases (ESBLs), and Gram-positive bacteria. SPR741, also called Potentiator, is a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant Gram-negative infections, such as Enterobacteriaceae. Klebsiella species and Escherichia coli (E. coli) are examples of Enterobacteriaceae and have become resistant to many standard of care antibiotics. SPR741 increases the spectrum and potency of more than two dozen classes of antibiotics to expand activity against multidrug resistant Gram-negative infections when used in combination. Spero Therapeutics also has a robust preclinical pipeline including SPR720, which is a preclinical oral asset for nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection. In addition, Spero Therapeutics has a variety of other discovery antimicrobials focused on drug-resistant infections.
For more information, please visit https://sperotherapeutics.com
Advertisement
Details of the panel discussions are as following:Session Name: Funding and Partnering with US Government AgenciesDate and time: Thursday, July 13, 2017 at 4:50 p.m. Eastern Time (ET)Location: Royal Sonesta, Baltimore
Advertisement
Session Name: Pricing and P&T Committee's Role in Determining Novel Antibiotic UsageDate and time: Friday, July 14, 2017 at 9:20 a.m. Eastern Time (ET)Location: Royal Sonesta, Baltimore
About SperoSpero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to developing a novel and highly differentiated pipeline of antibacterials focused on unmet needs of patients with drug resistant bacterial infections. Spero Therapeutics is advancing two lead programs in parallel, SPR994 and SPR741. SPR994 is a first in class oral agent that has demonstrated potent in vitro and in vivo activity against a wide variety of Gram-negative bacteria, including extended-spectrum beta-lactamases (ESBLs), and Gram-positive bacteria. SPR741, also called Potentiator, is a platform approach to combination therapy to treat serious and life-threatening multi-drug resistant Gram-negative infections, such as Enterobacteriaceae. Klebsiella species and Escherichia coli (E. coli) are examples of Enterobacteriaceae and have become resistant to many standard of care antibiotics. SPR741 increases the spectrum and potency of more than two dozen classes of antibiotics to expand activity against multidrug resistant Gram-negative infections when used in combination. Spero Therapeutics also has a robust preclinical pipeline including SPR720, which is a preclinical oral asset for nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection. In addition, Spero Therapeutics has a variety of other discovery antimicrobials focused on drug-resistant infections.
For more information, please visit https://sperotherapeutics.com
View original content:http://www.prnewswire.com/news-releases/spero-therapeutics-to-participate-in-anti-infectives-panel-discussions-at-the-2017-infectious-disease-summit-300485574.html
SOURCE Spero Therapeutics, Inc.
